Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

On August 30, 2018 Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, reported that Steven A. Shallcross, Interim Chief Executive Officer & Chief Financial Officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 9:35 a.m. ET (Press release, Synthetic Biologics, AUG 30, 2018, View Source [SID1234529194]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the web at View Source After the presentation, a replay will be archived and accessible for 60 days on Synthetic Biologics’ website, www.syntheticbiologics.com.

Akebia Therapeutics to Participate in Upcoming Investor Conferences

On August 30, 2018 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), reported that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences (Press release, Akebia, AUG 30, 2018, View Source [SID1234529193]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018, at 1:45 p.m. Eastern Time, at the St. Regis New York Hotel.

The 16th Annual Morgan Stanley Global Healthcare Conference on Friday, September 14, 2018, at 10:30 a.m. Eastern Time, at the Grand Hyatt New York.

A live webcast of the presentations will be available on the company’s website at www.akebia.com. To access, please log onto the Akebia website at least 15 minutes prior to the webcasts to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia’s website following the conferences.

Five Prime Therapeutics to Present at 2018 Wells Fargo Healthcare Conference

On August 30, 2018 Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the 2018 Wells Fargo Healthcare Conference, Sept. 6, 2018, at 2:30 pm ET (Press release, Five Prime Therapeutics, AUG 30, 2018, View Source [SID1234529192]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

Diplomat to Participate in Upcoming Investor Conferences

On August 30, 2018 Diplomat Pharmacy, Inc. (NYSE: DPLO), reported that executives will present at three upcoming investor conferences (Press release, Diplomat Speciality Pharmacy, AUG 30, 2018, View Source [SID1234529191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird Global Healthcare Conference in New York: Atul Kavthekar, chief financial officer, will present at 9:40 a.m. ET. Sept. 5.

Wells Fargo Securities Healthcare Conference in Boston: Brian Griffin, chairman and chief executive officer, and Atul Kavthekar, chief financial officer, will present at 8 a.m. ET. Sept. 6.

Morgan Stanley Global Healthcare Conference in New York: Brian Griffin, chairman and CEO; Joel Saban, president; and Atul Kavthekar, chief financial officer, will present at 11:40 a.m. ET. Sept. 12.

Live audio webcasts of each presentation will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. Recordings will be available for approximately 90 days following each presentation at the same URL.

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences

On August 30, 2018 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to
present at the following upcoming events (Press release, Arrowhead Pharmaceuticals, AUG 30, 2018, View Source [SID1234529190]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Annual B. Riley FBR Healthcare Conference– New York, September 4, 2018
Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investo relations, will participate in three panel
discussions

18th World Gastroenterologists Summit – Auckland, New Zealand, September 7-8, 2018
September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, "Hepatitis B in focus: New biology, new targets and real hope for finite therapy"

European Respiratory Society International Congress 2018 – Paris, September 15-19, 2018
September 16, 12:15 p.m. CEST –Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, " Targeting

ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis"

Antivirals: Targeting HBV and Beyond – Boston, September 25, 2018
September 25, 12:00 p.m. EDT –James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, "Using siRNA to target the HBV transcriptome"

A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentations conclude.